GeneDx Holdings Corp. (WGS)
NASDAQ (NGS) NASDAQ (NGS) Primary 
GeneDx Holdings: A Phenomenal Comeback With More Room To Run
GeneDx Holdings Corp. experienced a dramatic turnaround in 2024, achieving profitability and 100x returns, driven by reduced cash burn and strategic product innovations. Key growth catalysts include the NICU market expansion and pediatric neurology diagnostics, supported by faster turnaround times, non-invasive testing, and EHR integration. Financial improvements include a 44% revenue increase, higher reimbursement rates, and improved gross margins, positioning GeneDx favorably among its peers.
GeneDx Holdings (WGS) Surges 13.2%: Is This an Indication of Further Gains?
GeneDx Holdings (WGS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
This Once Ultracheap Biotech Stock Rockets 2,762%, Nears Buy Point After Big Earnings Win
Biotech stock GeneDx soared 50% after earnings on Oct. 29. Shares of the genetic testing company have soared 2,762% year to date.
Meet the Healthcare Stock That Produced Nvidia-Sized Gains in Less Than a Year
Meet the Healthcare Stock That Produced Nvidia-Sized Gains in Less Than a Year
GeneDx Holdings: Phenomenal Gains, More Upside Potential In Medium Term
GeneDx Holdings Corp. stock has risen by a scarcely believable >3,000% across the past year. The company provides exome sequencing products that can be used to search for and diagnose hundreds of genetic conditions. The company's Q3 earnings led to a >50% uplift in the share price this week, with ~$287 revenues pledged for 2024, and a gross margin of >60%.
GeneDx Holdings Corp. (WGS) Q3 2024 Earnings Call Transcript
GeneDx Holdings Corp. (NASDAQ:WGS ) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Sabrina Dunbar - Investor Relations Katherine Stueland - President and Chief Executive Officer Kevin Feeley - Chief Financial Officer Conference Call Participants Daniel Brennan - TD Cowen William Bonello - Craig Hallum Capital Group Mark Massaro - BTIG Matthew Sykes - Goldman Sachs Group, Inc. Brandon Couillard - Wells Fargo Securities Matthew Stanton - Jefferies Operator Thank you for standing by, and welcome to the GeneDx Third Quarter 2024 Earnings Conference Call. At this time all participants are in a listen-only mode and after the speaker's presentation we will have a question-and-answer session Keep in mind that this call is being recorded.
GeneDx Holdings Corp. (WGS) Tops Q3 Earnings and Revenue Estimates
GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.19 per share. This compares to loss of $0.82 per share a year ago.
GeneDx Holdings: Stock To Keep Outperforming As Business Momentum Persists
GeneDx Holdings Corp. leverages its genomic and data science expertise to provide precise medical diagnostics, focusing on rare diseases and pediatric exome/genome testing. The company's second-quarter performance exceeded expectations, driven by over 125% year-over-year growth in its whole exome and genome business, now 74% of total revenue. GeneDx reduced its quarterly cash burn significantly and anticipates profitability by 2025, with increasing reimbursement rates and expanding Medicaid coverage boosting revenue.
GeneDx Stock Rocketed 1310% In Dramatic Turnaround Powered By DNA Analytics
GeneDx is helping patients navigate through the "diagnostic odyssey" with DNA sequencing. The biotech stock is on its own odyssey.
How Much Upside is Left in GENEDX HOLDINGS (WGS)? Wall Street Analysts Think 40.34%
The consensus price target hints at a 40.3% upside potential for GENEDX HOLDINGS (WGS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
GeneDx Holdings Corp. (WGS) Q2 2024 Earnings Call Transcript
GeneDx Holdings Corp. (NASDAQ:WGS ) Q2 2024 Earnings Conference Call July 30, 2024 4:30 PM ET Company Participants Sabrina Dunbar - Commercial Chief of Staff Katherine Stueland - President and Chief Executive Officer Kevin Feeley - Chief Financial Officer Conference Call Participants Tycho Peterson - Jefferies William Bonello - Craig Hallum Mark Massaro - BTIG Daniel Brennan - TD Cowen Matthew Sykes - Goldman Sachs Operator Good day and thank you for standing by. Welcome to the GeneDx Second Quarter 2024 Earnings Conference Call.
GeneDx Holdings Corp. (WGS) Reports Q2 Loss, Tops Revenue Estimates
GeneDx Holdings Corp. (WGS) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $1.65 per share a year ago.
